share_log
Reuters ·  2024/11/15 17:01

Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B

Arbutus和Barinthus Bio宣佈了Im-Prove II試驗的新數據,顯示尼伏單抗的添加提高了慢性乙型肝炎患者Hbsag丟失的比率。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論